Fresh analysis suggests that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop traditional lifestyle programs.
Published data in a prominent medical journal shows that while obese individuals can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals buying such medications need to be aware of the risk of rapid rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.
This pace of regain implies a reversion to original mass within about a year and a half.
Comparing Treatments
The analysis, which looked at 37 of studies involving thousands of patients, contrasted the results of these new drugs with conventional dieting.
Researchers point out that people who lose weight through lifestyle changes alone typically see a slower weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts suggest the mechanism of the drugs explains the heightened regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means hunger is uncontrolled, making excessive eating far more likely."
A Chronic Disease?
The NHS recommend the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, considering the high risk of relapse, the therapy is often ongoing.
This perspective is supported by drug manufacturers, who say that the results "highlight the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Experiences
People who have come off the medication describe a powerful resurgence of cravings.
"It felt as if a trigger that goes on and I was suddenly ravenous," said a patient.
This challenge is exacerbated if individuals have not adopted permanent lifestyle or habit modifications during therapy.
Significant Use
Recent estimates show that a significant number of adults in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is higher among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and long-term success hinges on integrated behavioural support.
